Table 2.

Summary of the biological activities of synthetic CDXs obtained by binding/coupling chiral moieties to the xanthone scaffold.

CDXs	Biological Activities	Ref.
XAA, DMXAA and analogues 156–164	Antitumor,	[122,123,124,125,126,127,128,129,130,131,132,133,136]
	antiviral,	[134]
	antiplatelet, antithrombotic,	[135]
	anti-inflammatory	[137]
	and analgesic	[140]
Aminoalkanolic CDXs 165–243	Cyclooxygenases inhibition,	[160]
	antitumor,	[148]
	anticonvulsant,	[139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,167,171,175,176,177,178,179]
	cardiovascular,	[167,169,173,174,175,179,180]
	antiplatelet aggregation,	[181]
	antimutagenic,	[182]
	antifungal,	[170]
	antibacterial and	[172]
	anticancer	[183]
CDXs conjugated with amines, amino esters and amino acids 244–263	Anti-inflammatory	[168,172,186]
CDXs containing piperazine moieties and analogues 264–294	Anticonvulsant,	[165]
	antiplatelet aggregation,	[181]
	cardiovascular,	[173,187,188,189,190]
	antifungal and	[188]
	antibacterial	[172]
CDXs containing other moieties 295–310	No activities reported	[194]